1756 related articles for article (PubMed ID: 28705205)
21. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
Yao W; Wang W; Li G
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
[TBL] [Abstract][Full Text] [Related]
22. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
Mosquera C; Koutlas NJ; Fitzgerald TL
Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine tumors: analysis from a single-institution.
Zeng YJ; Liu L; Wu H; Lai W; Cao JZ; Xu HY; Wang J; Chu ZH
Asian Pac J Cancer Prev; 2013; 14(10):5775-81. PubMed ID: 24289577
[TBL] [Abstract][Full Text] [Related]
24. The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.
Wang C; Yu J; Fan Y; Ma K; Ning J; Hu Y; Niu W; Dong X; Wu Y; Li E; Dong D
Ann Clin Lab Sci; 2019 Sep; 49(4):448-456. PubMed ID: 31471333
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological Features of Gastroenteropancreatic Neuroendocrine Neoplasms.
Sekerci A; Turk HM; Demir T; Seker M; Akcakaya A; Arici DS
J Coll Physicians Surg Pak; 2020 Aug; 30(8):863-867. PubMed ID: 32893801
[TBL] [Abstract][Full Text] [Related]
26. Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.
Zhang XB; Fan YB; Jing R; Getu MA; Chen WY; Zhang W; Dong HX; Dakal TC; Hayat A; Cai HJ; Ashrafizadeh M; Abd El-Aty AM; Hacimuftuoglu A; Liu P; Li TF; Sethi G; Ahn KS; Ertas YN; Chen MJ; Ji JS; Ma L; Gong P
Mil Med Res; 2024 Jun; 11(1):35. PubMed ID: 38835066
[TBL] [Abstract][Full Text] [Related]
27. [Clinicopathological features of colorectal neuroendocrine neoplasms and prognostic significance of WHO staging system].
Zhang XH; Lu XL; Wu N; Liu B; Wang FY; Zhang RS; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):191-6. PubMed ID: 23769440
[TBL] [Abstract][Full Text] [Related]
28. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
29. Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years.
Desai GS; Pande P; Chhabra V; Shah RC; Jagannath P
Indian J Gastroenterol; 2019 Oct; 38(5):399-410. PubMed ID: 31802438
[TBL] [Abstract][Full Text] [Related]
30. Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland.
Alwan H; La Rosa S; Andreas Kopp P; Germann S; Maspoli-Conconi M; Sempoux C; Bulliard JL
Cancer Med; 2020 Dec; 9(24):9454-9461. PubMed ID: 33078908
[TBL] [Abstract][Full Text] [Related]
31. Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre.
Bazarbashi S; Aseafan M; Elgazzar T; Alkhayat M; Alghabban A; Abdelgawad MI; Alshamsan B; Alshibany A; Elhassan T; Aljubran A; Alzahrani A; Alhindi H; Raef H
BMC Endocr Disord; 2023 Apr; 23(1):74. PubMed ID: 37029347
[TBL] [Abstract][Full Text] [Related]
32. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
Klöppel G
Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
[TBL] [Abstract][Full Text] [Related]
33. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
[TBL] [Abstract][Full Text] [Related]
34. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
[No Abstract] [Full Text] [Related]
35. Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China.
Wang YH; Lin Y; Xue L; Wang JH; Chen MH; Chen J
BMC Endocr Disord; 2012 Nov; 12():30. PubMed ID: 23194346
[TBL] [Abstract][Full Text] [Related]
36. Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon.
Kourie HR; Ghorra C; Rassy M; Kesserouani C; Kattan J
Asian Pac J Cancer Prev; 2016; 17(5):2679-81. PubMed ID: 27268650
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.
Feola T; Puliani G; Sesti F; Modica R; Centello R; Minotta R; Cannavale G; Di Meglio S; Di Vito V; Lauretta R; Appetecchia M; Colao A; Lenzi A; Isidori AM; Faggiano A; Giannetta E
J Endocrinol Invest; 2022 Apr; 45(4):849-857. PubMed ID: 35040099
[TBL] [Abstract][Full Text] [Related]
38. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
39. Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges.
Garcia-Carbonero R
Cancer Metastasis Rev; 2014 Mar; 33(1):343-4. PubMed ID: 24357057
[No Abstract] [Full Text] [Related]
40. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]